Neoplasm Metastasis Clinical Trials

A listing of Neoplasm Metastasis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 3039 clinical trials
Patient-Reported AutoImmunity Secondary to Cancer immunothErapy (PRAISE)

This is a real life observational longitudinal study aiming to identify autoimmune manifestations in patients treated with "checkpoint inhibitors" in mono or combo therapy in real life. The study is based on patients reported experience validated by physician, recruited in cancer centers in France with another data collection from a …

  • 04 Oct, 2022
  • 1 location
First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors

The purpose of this study is to see how safe and effective ABBV-CLS-579 is when used alone and in combination with a PD-1 target agent or with a VEGF TKI. ABBV-CLS-579 is an investigational drug being developed for the treatment of tumors. The trial aims to establish a safe, tolerable, …

  • 04 Oct, 2022
  • 8 locations
Randomized, Open Label, Multicenter, Phase III Study of Entrectinib Versus Crizotinib in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring ROS1 Gene Rearrangements With and Without Central Nervous System Metastases

The study will compare the efficacy and safety of entrectinib with crizotinib in participants with advanced or metastatic ROS1 non-small cell lung cancer (NSCLC). The participants will self-administer oral entrectinib or crizotinib as described in the protocol and local prescribing information. Treatments will continue until progressive disease, unacceptable toxicity, death, …

proto-oncogene tyrosine-protein kinase ros
cancer chemotherapy
kinase inhibitor
systemic therapy
lung carcinoma
  • 27 Oct, 2022
  • 50 locations
Immunonutritional Supplement After Total Gastrectomy in Patients With Stage III Gastric Cancer (CRUCIAL)

support or normal diet after discharge. The primary and secondary outcomes will be collected.

  • 07 Oct, 2022
  • 1 location
  • 21 Oct, 2022
  • 48 locations
Imperial Valley Regional Occupational Program (IVROP) ReadyforLIFE Healthy Marriage and Responsible Fatherhood Program Evaluation

The purpose of the Imperial Valley Regional Occupational Program (IVROP) ReadyforLIFE program evaluation is to determine whether primary (i.e., behaviors) and secondary (i.e., attitudes

Accepts healthy volunteers
  • 14 Oct, 2022
  • 1 location
A Study of Nusinersen Among Participants With Spinal Muscular Atrophy Who Received Onasemnogene Abeparvovec (RESPOND)

onasemnogene abeparvovec. The secondary objectives of this study are to evaluate the safety and tolerability; and clinical outcomes following treatment with nusinersen in participants with SMA who

gene deletion
  • 07 Oct, 2022
  • 20 locations
STREAM Trial - Statins in Multimorbid Older Adults Without Cardiovascular Disease (STREAM)

Statins are among the most widely used drugs. While they were found to be effective for primary and secondary prevention of cardiovascular disease (CVD) in middle-aged subjects, their benefits

  • 04 Oct, 2022
Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis

of O. volvulus microfilaria in skin, the parasite that causes river blindness. Secondary purposes are to determine the effectiveness of moxidectin compared to ivermectin once or twice a year

  • 07 Oct, 2022
  • 1 location
A Phase 3 Randomized, Placebo-Controlled Trial With a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation (ATLAS)

(NF). The secondary objectives of this study are to evaluate the safety and tolerability of BIIB067 and to evaluate the effect of BIIB067 on pharmacodynamics (PD)/treatment response biomarkers when

  • 22 Oct, 2022
  • 27 locations